Just Launched! ACCURUN® TV/MG Molecular Positive Control This control is designed as a ready-to-use quality control solution to monitor day-to-day performance of TV and MG molecular assays. Order your controls today by clicking this link: https://hubs.ly/Q0303XPb0 #molecular #qualitycontrols #TVMG
About us
LGC Clinical Diagnostics develops and manufactures a comprehensive portfolio of catalog and custom-developed diagnostic quality solutions, biological and reagent component materials for the extended life sciences industry. Our scientific expertise, together with our custom product development capabilities, further accelerates bringing your innovations to life. Together, we are changing the future of diagnostics. LGC Clinical Diagnostics has over 35 years of experience as a leading and trusted global manufacturer of Quality Management Tools (QMT) and reagent components. We partner with In Vitro Diagnostics (IVD) and biopharmaceutical developers, clinical research organizations (CROs) and academic institutions in commercialization activities across the entire diagnostic pipeline - from concept and early-stage research, through expedited product development and onwards into routine clinical use. Laboratories and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics, and clinical genomics rely on LGC’s products to achieve accurate and reliable diagnostic results. Our combined and ever-growing capabilities mean we are better positioned to support the needs of the clinical diagnostics industry, from early feasibility and research to commercial & laboratory development test (LDT) assay development, installation, validation and ongoing performance monitoring support. LGC Clinical Diagnostics Quality Management and reagent component manufacturing facilities are FDA-registered, and ISO 13485 and ISO 9001-certified. Our brands include Technopath Clinical Diagnostics, SeraCare, Biochemical Diagnostics, Inc., KOVA International, Maine Standards, and The Native Antigen Company. Together, our brands serve over 7,500 customers in over 120 countries, providing products for more than 20 clinical application areas, including infectious diseases, NIPT, diabetes, cardiac disease and oncology.
- Website
-
https://lgcclinicaldiagnostics.com
External link for LGC Clinical Diagnostics
- Industry
- Biotechnology
- Company size
- 1,001-5,000 employees
- Headquarters
- Milford, Massachusetts
- Type
- Privately Held
- Specialties
- linearity and calibration verification, reference materials, antigens and antibodies, research components, biological materials, Quality Measurement Tools, Informatics, and Quality Controls
Locations
Employees at LGC Clinical Diagnostics
Updates
-
The time has come for...The Native Antigen Company's December edition of The Monthly Infectious Disease Summary! We've pulled together this month's most relevant news articles, highly engaging podcasts, free digital downloads and more just for you. So whether your on the lab bench or awaiting your results you can stay up to date by scrolling our newsletter. Read it now: https://hubs.ly/Q02_ZFcP0 #antigens #antibodies #infectiousdisease #newsletter
-
-
New Blog Post! Infectious complications are a significant concern for patients after solid organ transplants. Molecular testing is a vital tool for the prevention of these complications. Read our latest blog "Managing Transplant Patient Health with Molecular Diagnostics" so you can ensure the accuracy of this critical information being placed in clinicians’ hands. https://hubs.ly/Q02_QYjG0 #moleculardiagnostics #infectiousdiseases #transplantorganhealth
-
Our posters from #AMP2024 are here! They showcase key advancements in critical areas like ctDNA validation, DPYD genetic testing for chemotherapy toxicity, and FFPE reference materials for NGS-based assays. These insights are addressing complex challenges and sparking meaningful discussions. These breakthroughs have the potential to directly impact your work in precision medicine and molecular diagnostics - Don't miss out! Access Posters: https://hubs.ly/Q02_fBDm0 #ctDNA #DPYD #FFPE #PrecisionMedicine #NextGenSequencing #GeneticTesting #LiquidBiopsy #Pharmacogenomics #CancerResearch
-
-
𝐍𝐄𝐖 𝐏𝐑𝐎𝐃𝐔𝐂𝐓 🎉 𝐕𝐀𝐋𝐈𝐃𝐀𝐓𝐄® 𝐌𝐓𝐗 is now available for Roche cobas®! This is a brand new addition to our Therapeutic Drug Monitoring class! This product offers Methotrexate (MTX) for easy, fast, efficient calibration verification and linearity testing. 𝐖𝐡𝐲 𝐌𝐞𝐭𝐡𝐨𝐭𝐫𝐞𝐱𝐚𝐭𝐞? Methotrexate is an antineoplastic drug that is used in the treatment of Psoriasis, Rheumatoid Arthritis, and other autoimmune conditions. It works by decreasing inflammation, which can reduce pain and prevent long-term injury to the joints and skin. It may also be used to treat some types of cancer (i.e. non-Hodgkin Lymphomas, Osteosarcoma) It works by slowing down the growth of cancer cells. Methotrexate is extremely potent and levels are monitored to assess toxicity. 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://hubs.ly/Q02_0-gn0 #Methotrexate #TherapeuticDrugMonitoring #CalibrationVerification #ClinicalDiagnostics
-
-
We are very exited to share this news with all of our loyal customers, colleagues, and followers.
Expanding Innovation for our Core Laboratory Customers We have announced the acquisition of DiaMex GmbH, a company with a comprehensive portfolio of third-party serology controls, and, more recently, molecular controls. This acquisition will complement our existing quality control portfolio and enhance our choice of products. Together, we look forward to driving advancements in diagnostics, ensuring greater reliability, choice, and innovation for the global healthcare community. Click on the images to see what Kenneth Yoon and Bharathi Anekella say about the announcement. Read more at the link: https://lnkd.in/dbxVHJrt #ScienceforaSaferWorld LGC Clinical Diagnostics LGC Biosearch Technologies
-
-
New Product Announcement! We’re excited to introduce the Seraseq Solid Tumor FFPE DNA Reference Material, designed to address the challenges of #FFPE tissue samples in #GenomicProfiling. This material includes 74 biosynthetic DNA variants across 62 solid tumor-associated genes, featuring 37 SNVs, 18 deletions, 5 insertions, and 10 translocations. 65 of these variants are linked to FDA drug targets, offering a robust benchmark for clinical relevance. The material is provided in a lightly fixed FFPE format with clinically relevant allelic frequencies, ideal for testing assay sensitivity and detection limits. Learn more and access the complete table of mutations here: https://hubs.ly/Q02-ryRq0 #CancerDiagnostics #DNASequencing #ClinicalGenomics #AssayDevelopment #CancerResearch
-
-
Thank you for an incredible #AMP2024 in Vancouver! It was an absolute pleasure connecting with so many of you and sharing the latest advancements in clinical genomics. Our workshop and posters sparked great discussions, and we’re thrilled by the positive feedback and engagement we received. Stay tuned—we'll be sharing all the details of the scientific posters presented at AMP very soon! The excitement continues!
-
-
Excited to share our 2024 AACR poster on optimizing DNA extraction from Formalin-Fixed Paraffin-Embedded (#FFPE) tissues, crucial for cancer diagnostics. Our refined extraction methods significantly improve DNA yield and integrity, enhancing Homologous Recombination Deficiency (#HRD) detection—a key biomarker for cancer treatment. Access the full poster here: https://hubs.ly/Q02ZJXBZ0 Stay tuned for our upcoming launch of Seraseq® Solid Tumor FFPE DNA Reference Material, designed to further boost genomic profiling accuracy for FFPE samples in cancer research. #AACR2024 #CancerDiagnostics #GenomicProfiling #DNAExtraction #CancerResearch #Biomarkers #NextGenSequencing #PrecisionMedicine #SolidTumor #CancerTreatment
-
-
Reflecting on our time at #MEDICA2024, we had a truly successful experience connecting with industry leaders and strengthening our strategic partnerships. Key discussions with distributors, new partnerships and collaborations—these developments are paving the way for continued growth and innovation in our product offerings. We appreciate everyone who took the time to engage with us and look forward to building on these conversations!
-
-
-
-
-
+1
-